News
-
Both Teva and Sandoz have announced launches of generic naloxone nasal spray for the reversal of opioid overdose in the US, with Teva claiming first-to-market status. The Sandoz version is an authorized generic of Emergent… Read more . . .
-
According to Australian healthcare system Northern Health, the government of the state of Victoria will provide a $4.2 million grant to the University of Melbourne and Monash University to fund a clinical trial of intranasal… Read more . . .
-
Aridis Pharmaceuticals said that in vitro testing has demonstrated that its AR-701 monoclonal antibody (mAb) cocktail AR-701 has the ability to neutralize all SARS-CoV-2 variants, including Omicron, as well as the coronaviruses that cause SARS,… Read more . . .
-
According to Inhalation Sciences (ISAB), topline data from a clinical trial of ISAB’s PreciseInhale aerosol generating system successfully demonstrated that the system is capable of targeting a dose to a specific lung region and that… Read more . . .
-
Polyphor and EnBiotix have announced the initiation of Phase 1 trial of nebulized murepavadin in healthy volunteers; Polyphor had announced approval of a Phase 1 study by the MHRA in December 2020. The murepavadin inhalation… Read more . . .
-
The 2021 Drug Delivery to the Lungs conference featured a variety of topics of particular interest to the OINDP community in 2021, including COVID-19, digitalization, nasal drug delivery, and reducing the environmental impact of MDIs,… Read more . . .
-
Device maker H&T Presspart has acquired the rights to market Biocorp’s Inspair inhaler sensor, the two companies have announced. The Inspair sensor, which fits onto standard metered dose inhalers, records inhaler usage data; provides audio and visual… Read more . . .
-
Aerovate Therapeutics has initiated a Phase 2b/3 trial of its AV-101 imatinib DPI for the treatment of pulmonary arterial hypertension (PAH), the company said. The IMPAHCT trial is expected to enroll 462 PAH patients; the… Read more . . .
-
Lancaster University has announced that newly launched ViraCorp subsidiary ViraVac will develop a intranasal COVID-19 vaccine based on technology developed at Lancaster by Muhammad Munir, a lecturer in biomedicine. According to the announcement, “The company… Read more . . .
-
Memo Therapeutics said that a Swiss funding program for COVID-19 medicines has granted the company CHF 10.5 million for clinical development of the company’s COVAB 36 inhaled fully-human monoclonal antibody for the treatment of SARS-CoV-2… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden